59938-33-9

Basic information

• Product Name: 3-IODO-7-METHYL-IMIDAZO[1,2-A]PYRIDINE
• Synonyms: 3-IODO-7-METHYL-IMIDAZO[1,2-A]PYRIDINE;IMidazo[1,2-a]pyridine, 3-iodo-7-Methyl-
• CAS NO: 59938-33-9
• Molecular Formula: C8H7IN2
• Molecular Weight: 258.06
• Mol File: 59938-33-9.mol
• Article Data: 3

Chemical Properties

• Melting Point: 109-117°C
• Appearance: /
• Storage Temp.: ?20°C
• CAS DataBase Reference: 3-IODO-7-METHYL-IMIDAZO[1,2-A]PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-IODO-7-METHYL-IMIDAZO[1,2-A]PYRIDINE(59938-33-9)
• EPA Substance Registry System: 3-IODO-7-METHYL-IMIDAZO[1,2-A]PYRIDINE(59938-33-9)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26
• WGK Germany: 3
• Hazardous Substances Data: 59938-33-9(Hazardous Substances Data)

Usage

General Description

3-IODO-7-METHYL-IMIDAZO[1,2-A]PYRIDINE is a chemical compound with the molecular formula C7H6IN3. It is a heterocyclic organic compound containing both imidazole and pyridine rings, with a methyl and an iodo substituent. 3-IODO-7-METHYL-IMIDAZO[1,2-A]PYRIDINE is used as a building block in organic synthesis and can be utilized in the pharmaceutical industry as a starting material for the synthesis of various biologically active molecules. It has also been studied for its potential applications in medicinal chemistry, particularly in the development of new drugs and pharmaceutical products. Additionally, 3-IODO-7-METHYL-IMIDAZO[1,2-A]PYRIDINE has been investigated for its potential use in agrochemicals and other industrial applications.

Upstream product

• 695-34-1 2-Amino-4-methylpyridine 
• 874-39-5 7-Methyl-imidazo[1,2-a]pyridine 

Relevant articles and documents

From Synthetic Simplified Marine Metabolite Analogues to New Selective Allosteric Inhibitor of Aurora B Kinase

Significant inhibition of Aurora B was achieved by the synthesis of simplified fragments of benzosceptrins and oroidin belonging to the marine pyrrole-2-aminoimidazoles metabolites isolated from sponges. Evaluation of kinase inhibition enabled the discovery of a synthetically accessible rigid acetylenic structural analogue EL-228 (1), whose structure could be optimized into the potent CJ2-150 (37). Here we present the synthesis of new inhibitors of Aurora B kinase, which is an important target for cancer therapy through mitosis regulation. The biologically oriented synthesis yielded several nanomolar inhibitors. The optimized compound CJ2-150 (37) showed a non-ATP competitive allosteric mode of action in a mixed-type inhibition for Aurora B kinase. Molecular docking identified a probable binding mode in the allosteric site "F"and highlighted the key interactions with the protein. We describe the improvement of the inhibitory potency and specificity of the novel scaffold as well as the characterization of the mechanism of action.

NEW COMPOUNDS

The invention relates to new bicyclic heterocyclic derivative compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.